The Strategies of Pathogen-Oriented Therapy on Circumventing Antimicrobial Resistance

Overview

Journal Research (Wash D C)

Specialty Biology

Date 2020 Oct 21

PMID 33083786

Citations 16

Authors

Zifang Shang

Siew Yin Chan

Qing Song

Peng Li

Wei Huang

Affiliations

Soon will be listed here.

Abstract

The emerging antimicrobial resistance (AMR) poses serious threats to the global public health. Conventional antibiotics have been eclipsed in combating with drug-resistant bacteria. Moreover, the developing and deploying of novel antimicrobial drugs have trudged, as few new antibiotics are being developed over time and even fewer of them can hit the market. Alternative therapeutic strategies to resolve the AMR crisis are urgently required. Pathogen-oriented therapy (POT) springs up as a promising approach in circumventing antibiotic resistance. The tactic underling POT is applying antibacterial compounds or materials directly to infected regions to treat specific bacteria species or strains with goals of improving the drug efficacy and reducing nontargeting and the development of drug resistance. This review exemplifies recent trends in the development of POTs for circumventing AMR, including the adoption of antibiotic-antibiotic conjugates, antimicrobial peptides, therapeutic monoclonal antibodies, nanotechnologies, CRISPR-Cas systems, and microbiota modulations. Employing these alternative approaches alone or in combination shows promising advantages for addressing the growing clinical embarrassment of antibiotics in fighting drug-resistant bacteria.

Citing Articles

Precise Clearance of Intracellular MRSA via Internally and Externally Mediated Bioorthogonal Activation of Micro/Nano Hydrogel Microspheres.

Yang J, Chen L, Cai Z, Pang L, Huang Y, Xiao P Adv Sci (Weinh). 2024; 11(44):e2402370.

PMID: 39342650 PMC: 11600240. DOI: 10.1002/advs.202402370.

An Overview of the Recent Advances in Antimicrobial Resistance.

Oliveira M, Antunes W, Mota S, Madureira-Carvalho A, Dinis-Oliveira R, Dias da Silva D Microorganisms. 2024; 12(9).

PMID: 39338594 PMC: 11434382. DOI: 10.3390/microorganisms12091920.

Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.

Wei X, Zhou D, Xu C, Chen P, Chen S, Cheng Z Antibiotics (Basel). 2024; 13(9).

PMID: 39334985 PMC: 11429200. DOI: 10.3390/antibiotics13090810.

Solvent-Induced Lignin Conformation Changes Affect Synthesis and Antibacterial Performance of Silver Nanoparticle.

Li D, Chen L Nanomaterials (Basel). 2024; 14(11).

PMID: 38869582 PMC: 11173806. DOI: 10.3390/nano14110957.

Prevalence, pandemic, preventions and policies to overcome antimicrobial resistance.

Alotaibi G Saudi J Biol Sci. 2024; 31(8):104032.

PMID: 38854892 PMC: 11157277. DOI: 10.1016/j.sjbs.2024.104032.

References

Nichols D, Cahoon N, Trakhtenberg E, Pham L, Mehta A, Belanger A . Use of ichip for high-throughput in situ cultivation of "uncultivable" microbial species. Appl Environ Microbiol. 2010; 76(8):2445-50. PMC: 2849220. DOI: 10.1128/AEM.01754-09. View

Brown J, Koshland M . Activation of antibody Fc function by antigen-induced conformational changes. Proc Natl Acad Sci U S A. 1975; 72(12):5111-5. PMC: 388886. DOI: 10.1073/pnas.72.12.5111. View

Pickar-Oliver A, Gersbach C . The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019; 20(8):490-507. PMC: 7079207. DOI: 10.1038/s41580-019-0131-5. View

Kempf I, Jouy E, Chauvin C . Colistin use and colistin resistance in bacteria from animals. Int J Antimicrob Agents. 2016; 48(6):598-606. DOI: 10.1016/j.ijantimicag.2016.09.016. View

Yang X, Wei Q, Shao H, Jiang X . Multivalent Aminosaccharide-Based Gold Nanoparticles as Narrow-Spectrum Antibiotics in Vivo. ACS Appl Mater Interfaces. 2019; 11(8):7725-7730. DOI: 10.1021/acsami.8b19658. View

Gao W, Chen Y, Zhang Y, Zhang Q, Zhang L . Nanoparticle-based local antimicrobial drug delivery. Adv Drug Deliv Rev. 2017; 127:46-57. PMC: 5860926. DOI: 10.1016/j.addr.2017.09.015. View

Li Y, Cai H, Wang Z, Xu J, Fang J . Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 43(4):445-57. DOI: 10.1111/apt.13492. View

Nomura S, Hanaki H, Nagayama A . Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. J Chemother. 1997; 9(2):89-94. DOI: 10.1179/joc.1997.9.2.89. View

Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

10.

Hamamoto K, Kida Y, Zhang Y, Shimizu T, Kuwano K . Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol. 2003; 46(11):741-9. DOI: 10.1111/j.1348-0421.2002.tb02759.x. View

11.

Phillips O, Sharaf L . Oxazolidinone antimicrobials: a patent review (2012-2015). Expert Opin Ther Pat. 2016; 26(5):591-605. DOI: 10.1517/13543776.2016.1168807. View

12.

Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R . Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol. 2012; 19(3):377-85. PMC: 3294626. DOI: 10.1128/CVI.05589-11. View

13.

Fernandes P, Martens E . Antibiotics in late clinical development. Biochem Pharmacol. 2016; 133:152-163. DOI: 10.1016/j.bcp.2016.09.025. View

14.

Appelbaum P, Hunter P . The fluoroquinolone antibacterials: past, present and future perspectives. Int J Antimicrob Agents. 2001; 16(1):5-15. DOI: 10.1016/s0924-8579(00)00192-8. View

15.

Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gomez-Llorente C, Gil A . Probiotic mechanisms of action. Ann Nutr Metab. 2012; 61(2):160-74. DOI: 10.1159/000342079. View

16.

Varshney A, Kuzmicheva G, Lin J, Sunley K, Bowling Jr R, Kwan T . A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018; 13(1):e0190537. PMC: 5783355. DOI: 10.1371/journal.pone.0190537. View

17.

Hidalgo-Cantabrana C, Goh Y, Pan M, Sanozky-Dawes R, Barrangou R . Genome editing using the endogenous type I CRISPR-Cas system in . Proc Natl Acad Sci U S A. 2019; 116(32):15774-15783. PMC: 6690032. DOI: 10.1073/pnas.1905421116. View

18.

Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P . Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2018; 234(5):5628-5642. DOI: 10.1002/jcp.27419. View

19.

Wenzel M, Chiriac A, Otto A, Zweytick D, May C, Schumacher C . Small cationic antimicrobial peptides delocalize peripheral membrane proteins. Proc Natl Acad Sci U S A. 2014; 111(14):E1409-18. PMC: 3986158. DOI: 10.1073/pnas.1319900111. View

20.

Pini A, Falciani C, Mantengoli E, Bindi S, Brunetti J, Iozzi S . A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J. 2009; 24(4):1015-22. DOI: 10.1096/fj.09-145474. View